bcl-2 expression, p53 accumulation, and apoptosis in ovarian carcinomas

American Journal of Clinical Pathology

Volumn 105, Issue 3, 1996, Pages 341-349

  Diebold, Joachim ^a   Baretton, Gustavo ^a   Felchner, Matthias ^a   Meier, Werner ^b   Dopfer, Karin ^a   Schmidt, Michael ^a   Löhrs, Udo ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b Department of Gynecology ^*  (Germany)

Author keywords

Apoptosis; bcl 2; DNA fragmentation; Immunohistochemistry; Ovarian carcinomas; p53; Prognosis

Indexed keywords

ONCOPROTEIN; PROTEIN P53;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER GRADING; CANCER SURVIVAL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DETERMINATION;

EID: 0029869896     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcp/105.3.341     Document Type: Article

References (51)

1. Bast RC Jr, Boyer CM, Jacobs I, et al. Cell growth regulation in epithelial ovarian cancer. Cancer 1993;71:1597-1601.
2. Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/ neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-712.
3. Berchuck A, Rodriguez G, Kinney RB, et al. Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease. Am J Obstet Gynecol 1991;164:15-21.
4. Meden H, Marx D, Rath W, et al. Overexpression of the oncogene c-erb B2 in primary ovarian cancer: evaluation of the prognostic value in a Cox proportional hazards multiple regression. Int J Gynecol Pathol 1994;13:45-53.
5. Zhou DJ, Gonzalez Cadavid N, Ahuja H, et al. A unique pattern of proto-oncogene abnormalities in ovarian adenocarcinomas. Cancer 1988;62:1573-1576.
6. Tashiro H, Miyazaki K, Okamura H, Iwai A, Fukumoto M. c-myc over-expression in human primary ovarian tumours: Its relevance to tumour progression. Int J Cancer 1992;50:828-833.
7. Kohler MF, Marks JR, Wiseman RW, et al. Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst 1993;85:1513-1519.
8. Kupryjanczyk J, Thor AD, Beauchamp R, et al. p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci USA 1993;90:4961-4965.
9. Marks JR, Davidoff AM, Kerns BJ, et al. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 1991;51: 2979-2984.
10. Okamoto A, Sameshima Y, Yokoyama S, et al. Frequent allelic losses and mutations of the p53 gene in human ovarian cancer. Cancer Res 1991;51:5171-5176.
11. Bosari S, Viale G, Radaelli LJ, et al. p53 accumulation in ovarian carcinomas and its prognostic implications. Hum Pathol 1993;24:1175-1179.
12. Boltz EM, Kefford RF, Leary JA, Houghton CR, Friedlander ML. Amplification of c-ras-Ki oncogene in human ovarian tumours. Int J Cancer 1989;43:428-430.
13. van't Veer LJ, Hermens R, van den Berg Bakker LA, et al. ras oncogene activation in human ovarian carcinoma. Oncogene 1988;2:157-165.
14. Kacinski BM, Carter D, Mittal K, et al. Ovarian adenocarcinomas express fms-complementary transcripts and fms antigen, often with coexpression of CSF-1. Am J Pathol 1990;137:135-147.
15. Kerr JF, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer 1994;73:2013-2026.
16. Reed JC. Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994;124:1-6.
17. Stewart BW. Mechanisms of apoptosis: integration of genetic, biochemical, and cellular indicators. J Natl Cancer Inst 1994;86: 1286-1296.
18. Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes: Regulators of cell death. Blood 1992;80:879-886.
19. Cleary ML, Smith SD, Sklar J. Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell 1986;47:19-28.
20. Cleary ML, Sklar J. Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. Proc Natl Acad Sci USA 1985;82:7439-7443.
21. Bakhshi A, Jensen JP, Goldman P, et al. Cloning the chromosomal breakpoint of t(14;18) human lymphomas: Clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell 1985;41:899-906.
22. Nunez G, London L, Hockenbery D, et al. Deregulated bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J Immunol 1990;144:3602-3610.
23. Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988;335:440-442.
24. Wang Y, Szekely L, Okan I, Klein G, Wiman KG. Wild-type p53-triggered apoptosis is inhibited by bcl-2 in a v-myc-induced T-cell lymphoma line. Oncogene 1993;8:3427-3431.
25. Ryan JJ, Prochownik E, Gottlieb CA, et al. c-myc and bcl-2 modulate p53 function by altering p53 subcellular trafficking during the cell cycle. Proc Natl Acad Sci USA 1994;91:5878-5882.
26. Chiou SK, Rao L, White E. Bcl-2 blocks p53-dependent apoptosis. Mol Cell Biol 1994;14:2556-2563.
27. Hockenbery DM, Zutter M, Hickey W, Nahm M, Korsmeyer SJ. Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Nail Acad Sci USA 1991;88: 6961-6965.
28. Pezzella F, Turley H, Kuzu I, et al. Bcl-2 protein in non-small-cell lung carcinoma. N Engl J Med 1993;329:690-694.
29. Pilotti S, Collini P, Del Bo R, et al. A novel panel of antibodies that segregates immunocytochemically poorly differentiated carcinoma from undifferentiated carcinoma of the thyroid gland. Am J Surg Pathol 1994;18:1054-1064.
30. Pilotti S, Collini P, Rilke F, et al. Bcl-2 protein expression in carcinomas originating from the follicular epithelium of the thyroid gland. J Pathol 1994;172:337-342.
31. Gavrieli Y, Sherman Y, Ben Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992;119:493-501.
32. Ansari B, Coates PJ, Greenstein BD, Hall PA. In situ end-labelling detects DNA strand breaks in apoptosis and other physiological and pathological states. J Pathol 1993;170:1-8.
33. Wyllie AH, Arends MJ, Morris RG, Walker SW, Evan G. The apoptosis endonuclease and its regulation. Semin Immunol 1992;4:389-397.
34. Petersson F. Annual Report on Gynecological Cancer of FIGO. vol 20. Stockholm: Panorama Press, 1988
35. Cordell JL, Falini B, Erber WN, et al. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 1984;32:219-229.
36. Platz CE, Benda JA. Female genital tract cancer. Cancer 1995;75(Suppl):270-294.
37. Statistisches Bundesamt. Statistisches Jahrbuch 1993 für die Bundesrepublik Deutschland. Gesundheitswesen: Metzler/ Poeschel, 1993, pp 468-475.
38. Cannistra SA. Cancer of the ovary. N Engl J Med 1993;329:1550-1559.
39. Berchuck A, Kohler MF, Hopkins MP, et al. Overexpression of p53 is not a feature of benign and early-stage borderline epithelial ovarian tumors. Gynecol Oncol 1994;52:232-236.
40. Hartmann LC, Podratz KC, Keeney GL, et al. Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol 1994;12:64-69.
41. Lane DP. A death in the life of p53. Nature 1993;362:786-787.
42. Lane DP. p53, guardian of the genome. Nature 1992;358:15-16.
43. Rodenburg CJ, Ploem Zaaijer JJ, Cornelisse CJ, et al. Use of DNA image cytometry in addition to flow cytometry for the study of patients with advanced ovarian cancer. Cancer Res 1987;47: 3938-3941.
44. Gaulard P, d'Agay MF, Peuchmaur M, et al. Expression of the bcl-2 gene product in follicular lymphoma. Am J Pathol 1992;140: 1089-1095.
45. Pezzella F, Morrison H, Jones M, et al. Immunohistochemical detection of p53 and bcl-2 proteins in non-Hodgkin's lymphoma. Histopathology 1993;22:39-44.
46. Piris MA, Pezzella F, Martinez Montero JC, et al. p53 and bcl-2 expression in high-grade B-cell lymphomas: Correlation with survival time. Br J Cancer 1994;69:337-341.
47. Sinicrope FA, Ruan SB, Cleary KR, et al, bcl-2 and p53 oncoprotein expression during colorectal tumorigenesis. Cancer Res 1995;55:237-241.
48. Silvestrini R, Veneroni S, Daidone MG, et al. The bcl-2 protein: A prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J Natl Cancer Inst 1994;86:499-504.
49. Yin XM, Oltval ZN, Korsmeyer SJ. BH1 and BH2 domains of bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 1994;369:321-323.
50. Chleq Deschamps CM, LeBrun DP, Huie P, et al. Topographical dissociation of BCL-2 messenger RNA and protein expression in human lymphoid tissues. Blood 1993;81:293-298.
51. Staunton MJ, Gaffney EF. Tumor type is a determinant of susceptibility to apoptosis. Am J Clin Pathol 1995;103:300-307.